Histopathological characteristics of 2 groups of HIV-associated aggressive B lymphomas with or without MYC rearrangement
| . | Patients with MYC+ n = 43 . | Patients with MYC– n = 112 . | Total N = 155 . | P value . |
|---|---|---|---|---|
| Histology | ||||
| DLBCL NOS | 25 (58%) | 104 (93%) | 129 (83%) | .0001 |
| HGBCL NOS | 8 (19%) | 8 (7%) | 16 (10%) | .036 |
| HGBCL DH-TH | 10 (23%) | 0 | 10 (7%) | - |
| Median Ki67% (range) | 91 (40-100) | 85 (40-100) | 90 (40-100) | .012 |
| Ki67 ≥90% | 25/38∗ (66%) | 38/83∗ (46%) | 63/121∗ (52%) | .041 |
| DEL† | 15/39∗ (38%) | 27/95∗ (28%) | 42/134∗ (31%) | ns |
| BCL2 translocation | 6/43 (14%) | 3/93∗ (3%) | 9/136∗ (7%) | .019 |
| BCL6 translocation | 7/40∗,‡ (17%) | 25/91∗ (27%) | 32/131∗ (24%) | ns |
| EBV–encoded RNA positive | 3/14∗ (21%) | 17/52∗ (33%) | 20/66∗ (30%) | ns |
| COO GCB | 25/32∗ (87%) | 45/91∗ (49%) | 73/123∗ (59%) | .0001 |
| COO non-GCB | 5/32∗ (16%) | 46/91∗ (51%) | 51/123∗ (41%) |
| . | Patients with MYC+ n = 43 . | Patients with MYC– n = 112 . | Total N = 155 . | P value . |
|---|---|---|---|---|
| Histology | ||||
| DLBCL NOS | 25 (58%) | 104 (93%) | 129 (83%) | .0001 |
| HGBCL NOS | 8 (19%) | 8 (7%) | 16 (10%) | .036 |
| HGBCL DH-TH | 10 (23%) | 0 | 10 (7%) | - |
| Median Ki67% (range) | 91 (40-100) | 85 (40-100) | 90 (40-100) | .012 |
| Ki67 ≥90% | 25/38∗ (66%) | 38/83∗ (46%) | 63/121∗ (52%) | .041 |
| DEL† | 15/39∗ (38%) | 27/95∗ (28%) | 42/134∗ (31%) | ns |
| BCL2 translocation | 6/43 (14%) | 3/93∗ (3%) | 9/136∗ (7%) | .019 |
| BCL6 translocation | 7/40∗,‡ (17%) | 25/91∗ (27%) | 32/131∗ (24%) | ns |
| EBV–encoded RNA positive | 3/14∗ (21%) | 17/52∗ (33%) | 20/66∗ (30%) | ns |
| COO GCB | 25/32∗ (87%) | 45/91∗ (49%) | 73/123∗ (59%) | .0001 |
| COO non-GCB | 5/32∗ (16%) | 46/91∗ (51%) | 51/123∗ (41%) |
EBV, Epstein-Barr virus; GCB, germinal center B; HGBCL DH-TH, high-grade B-cell lymphoma “double or triple hit”; ns, not significant.
Denominators regard assessed patients.
The double expression was considered in the entire series (DLBCL NOS; HGBCL NOS; and HGBCL DH-TH).
In 3 patients with HGBCL DH-TH, BCL6 translocation was not available.